|
|
PVCT Provectus Biopharmaceuticals
|
|
||
Re: What do I say to the naysayers that suggest we need 50-100 patient P2 data for BTD or AA in indications like NETs or MUM? The FDA only cares about data, the share price only cares about data, the company needs to show unequivocal data, nothing will happen before the data. End of rant. |
return to message board, top of board |